Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

BioXcel Soars as Psychiatric Drug Approved With Broad Label (1)

April 6, 2022, 4:03 PM

(Updates shares, adds BofA commentary.)

BioXcel Therapeutics gains as much as 24%, the most intraday since July 2020, after winning broad approval for its first drug, a sedative used in patients with schizophrenia or bipolar disorder.

  • Truist analyst Robyn Karnauskas says the broad approval -- including in mild-to-moderate as well as geriatric patients -- bodes well for the treatment in the larger dementia market
    • She says the label warning on bradycardia and hypotension was not surprising and while the therapy has to be given by a health-care provider, “it looks like it can be given in multiple settings”
  • BofA analyst ...